Table 2 Loss of BTNL9 expression may promote drug resistance toward many targeted therapies in CGP, CCLE, and CTRP cohorts
From: Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma
| Â | Drug | Target | t-value | p-value |
|---|---|---|---|---|
| Â | IOX2 | EGLN1 | 5.91996 | 4.56E-09 |
| Â | PHA-793887 | CDK9 | 4.92172 | 1.02E-06 |
| Â | OSI-027 | MTOR | 4.55428 | 5.99E-06 |
| Â | Ispinesib | KIF11 | 4.42265 | 1.09E-05 |
| Â | Nilotinib | ABL1 | 4.3886 | 1.30E-05 |
| Â | Axitinib | PDGFRA | 4.33456 | 1.64E-05 |
|  | NG25 | MAP 4 K2 | 4.29746 | 1.92E-05 |
| Â | Nilotinib | KIT | 4.26379 | 2.26E-05 |
| Â | BMS345541 | IKBKB | 4.12048 | 4.13E-05 |
| Â | GSK525762A | BRD2 | 3.92075 | 9.50E-05 |
| Â | CAY10603 | HDAC6 | 3.91591 | 9.69E-05 |
| Â | TubastatinA | HDAC6 | 3.89552 | 0.000105 |
| Â | GSK525762A | BRD4 | 3.83187 | 0.000136 |
CGP dataset | PHA-793887 | CDK1 | 3.4184 | 0.000658 |
| Â | Fluorouracil | TYMS | 3.09815 | 0.002008 |
| Â | TPCA-1 | IKBKB | 3.09042 | 0.002061 |
|  | 1,256,580–46-7 | ALK | 3.01459 | 0.002646 |
| Â | CAL-101 | PIK3CD | 2.99145 | 0.002852 |
| Â | Belinostat | HDAC6 | 2.82403 | 0.004852 |
| Â | AT7519 | CDK9 | 2.81016 | 0.00506 |
| Â | CP-466722 | ATM | 2.78047 | 0.005542 |
| Â | Enzastaurin | PRKCB | 2.76951 | 0.00573 |
| Â | SB590885 | BRAF_V600E.Mutation | 2.6446 | 0.008337 |
| Â | Vorinostat | HDAC6 | 2.54112 | 0.011233 |
|  | Nutlin-3 | MDM2 | −2.94731 | 0.003295 |
|  | Dasatinib | EPHA2 | −3.23912 | 0.001305 |
|  | Quizartinib | FLT3 | −3.33865 | 0.000877 |
|  | 1,173,900–33-8 | PIK3CB | −3.55986 | 0.00039 |
|  | Linifanib | FLT3 | −5.1822 | 2.71E-07 |
|  | 870,483–87-7 | CSF1R | −9.60837 | 7.14E-21 |
CCLE dataset | Panobinostat | HDAC1 | 3.29253 | 0.001066 |
| Â | abraxane | TUBB | 2.83794 | 0.00473 |
| Â | Palbociclib | RB1 | 2.64989 | 0.008358 |
| Â | Topotecan | TOP1 | 2.45344 | 0.014498 |
|  | Sorafenib | FLT3 | −4.25026 | 2.56E-05 |
CTRP dataset | 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione | NR3C1 | 5.30047 | 1.51E-07 |
| Â | abraxane | TUBB | 4.50938 | 7.51E-06 |
| Â | Alisertib | AURKB | 4.50069 | 7.83E-06 |
| Â | PAC-1 | CASP3 | 4.27611 | 2.16E-05 |
|  | 660,868–91-7 | PLK1 | 4.21764 | 2.79E-05 |
| Â | Gossypol | BCL2 | 4.19093 | 3.12E-05 |
| Â | Decitabine | DNMT1 | 4.18042 | 3.24E-05 |
|  | 722,544–51-6 | AURKB | 4.14645 | 3.74E-05 |
| Â | Etoposide | TOP2B | 4.0066 | 6.76E-05 |
| Â | 3,5-bis(4-methylbenzylidene)piperidin-4-one | USP13 | 3.92444 | 9.47E-05 |
|  | 180,002–83-9 | CNR2 | 3.91953 | 9.68E-05 |
| Â | CICLOPIROX | RRM1 | 3.90668 | 0.000102 |
| Â | Dabrafenib | BRAF_V600E.Mutation | 3.84863 | 0.00014 |
|  | BRD-K62801835–001–01-0 | EZH2 | 3.80929 | 0.000151 |
| Â | BI2536 | PLK1 | 3.69725 | 0.000233 |
| Â | Nilotinib | ABL1 | 3.67464 | 0.000255 |
| Â | Cerulenin | HMGCS1 | 3.66163 | 0.000268 |
| Â | TW-37 | BCL2 | 3.585 | 0.000358 |
| Â | zebularine | DNMT1 | 3.57912 | 0.000366 |
| Â | Pevonedistat | NAE1 | 3.55057 | 0.000409 |
| Â | BAS02002358 | GPER1 | 3.52883 | 0.000442 |
| Â | KU-60019 | ATM | 3.52842 | 0.000443 |
| Â | narciclasine | RHOA | 3.47702 | 0.000536 |
| Â | Ki8751 | PDGFRA | 3.43765 | 0.000619 |
| Â | 4ly1 | HDAC1 | 3.39584 | 0.000719 |
| Â | SCHEMBL12182311 | EIF4E | 3.35831 | 0.000822 |
| Â | Belinostat | HDAC1 | 3.35122 | 0.000886 |
| Â | Masitinib | PDGFRA | 3.32101 | 0.000941 |
| Â | BIBR1532 | TERT | 3.31812 | 0.000949 |
| Â | UNII-UZ77T1VFBM | BIRC5 | 3.30878 | 0.000985 |
| Â | Nutlin-3 | MDM2 | 3.2982 | 0.001018 |
| Â | CHEMBL2058177 | EIF4E | 3.29052 | 0.001045 |
| Â | NSC373989 | MDM2 | 3.24218 | 0.001239 |
| Â | Imatinib | ABL1 | 3.22213 | 0.001327 |
| Â | Tacrolimus | PPP3CB | 3.13945 | 0.001761 |
| Â | Olaparib | PARP1 | 3.07789 | 0.002159 |
| Â | SMR001317659 | PDE4A | 3.03729 | 0.002467 |
| Â | Axitinib | PDGFRA | 3.02572 | 0.002563 |
| Â | Pubchem_92131101 | KIF11 | 3.01909 | 0.002617 |
| Â | abraxane | TUBB1 | 3.01218 | 0.002678 |
| Â | GSK461364 | PLK1 | 2.97879 | 0.002987 |
| Â | Sorafenib | PDGFRA | 2.93438 | 0.003443 |
| Â | Nutlin-3 | TP53 | 2.88952 | 0.003968 |
| Â | SMR000068650 | S1PR2 | 2.88871 | 0.003992 |
| Â | MK-1775 | WEE1 | 2.88827 | 0.003985 |
|  | BRD-K53855319–001–01-2 | SIRT1 | 2.87063 | 0.004217 |
| Â | Apicidin | HDAC1 | 2.7849 | 0.005485 |
| Â | TelomeraseInhibitorIX | TERT | 2.7825 | 0.005527 |
| Â | Pluripotin | MAPK1 | 2.76988 | 0.005741 |
| Â | PHA-793887 | CDK1 | 2.75543 | 0.005999 |
| Â | Vorinostat | HDAC1 | 2.74595 | 0.006174 |
| Â | I-BET151 | BRD4 | 2.73756 | 0.006332 |
| Â | SCHEMBL12182311 | EIF4A2 | 2.68306 | 0.007448 |
|  | 112,522–64-2 | HDAC2 | 2.66828 | 0.007855 |
| Â | RG108 | DNMT1 | 2.65008 | 0.008212 |
| Â | PF184 | IKBKB | 2.63052 | 0.008701 |
| Â | Pazopanib | PDGFRA | 2.63026 | 0.008704 |
| Â | JQ-1 | BRD4 | 2.59578 | 0.009615 |
| Â | SCHEMBL13833318 | HDAC1 | 2.56094 | 0.010633 |
| Â | CAY10603 | HDAC6 | 2.55261 | 0.010887 |
| Â | GSK525762A | BRD4 | 2.51599 | 0.012071 |
| Â | 4CA-0620 | PLK1 | 2.43094 | 0.01529 |
| Â | BCP9000801 | MDM2 | 2.41963 | 0.015783 |
| Â | Belinostat | HDAC6 | 2.37335 | 0.018128 |
| Â | Tipifarnib | FNTA | 2.36404 | 0.018536 |
| Â | prima-1 | TP53 | 2.35318 | 0.018879 |
| Â | BMS345541 | IKBKB | 2.35317 | 0.018872 |
| Â | Gemcitabine | RRM1 | 2.3315 | 0.019984 |
| Â | SMR001317659 | PDE4B | 2.28061 | 0.022841 |
| Â | Doxorubicin | TOP2B | 2.26369 | 0.023866 |
| Â | Rigosertib | PIK3CA | 2.22431 | 0.026433 |
|  | 3,5-di-tert-butylchalcone | RARA | −2.40858 | 0.016249 |
|  | Dasatinib | EPHA2 | −2.95126 | 0.003261 |